• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Genelux Corporation

    2/2/24 4:06:25 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNLX alert in real time by email
    SC 13G 1 d764964dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    GENELUX CORPORATION

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    36870H103

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 36870H103    SCHEDULE 13G    Page 2 of 5

     

     1   

     NAME OF REPORTING PERSON

     

     Aladar Szalay

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     4,180,305 (1)

       6   

     SHARED VOTING POWER

     

     5,000 (2)

       7   

     SOLE DISPOSITIVE POWER

     

     4,180,305 (1)

       8   

     SHARED DISPOSITIVE POWER

     

     5,000 (2)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,185,305 (3)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     15.7% (4)

    12  

     TYPE OF REPORTING PERSON

     

     IN

     

    (1)

    Consists of (i) 1,371,545 shares of common stock held by The Szalay 2010 Retained Annuity Trust, (ii) 2,258,760 shares of common stock held by The Szalay 2009 Irrevocable Trust and (iii) 550,000 shares of common stock held by The Szalay 2010 Children’s Trust, for which the reporting person has sole voting and dispositive power.

    (2)

    Consists of 5,000 shares of common stock held by the reporting person’s spouse, for which the reporting person has shared voting and dispositive power.

    (3)

    Consists of (i) 1,371,545 shares of common stock held by The Szalay 2010 Retained Annuity Trust, (ii) 2,258,760 shares of common stock held by The Szalay 2009 Irrevocable Trust and (iii) 550,000 shares of common stock held by The Szalay 2010 Children’s Trust, for which the reporting person has sole voting and dispositive power, and (iv) 5,000 shares of common stock held by the reporting person’s spouse, for which the reporting person has shared voting and dispositive power.

    (4)

    This percentage is calculated based on 26,717,676 shares of common stock outstanding as of November 8, 2023, as reported in Genelux Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission on November 14, 2023.


    CUSIP No. 36870H103    SCHEDULE 13G    Page 3 of 5

     

    Item 1(a).

    Name of Issuer:

    Genelux Corporation

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    2625 Townsgate Road, Suite 230

    Westlake Village, California 91361

     

    Item 2(a).

    Names of Person Filing:

    Aladar Szalay

     

    Item 2(b).

    Address of Principal Business Office, or, if none, Residence:

    7704 North Fork Rd., Highland, CA 92346

     

    Item 2(c).

    Citizenship:

    United States

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 per share

     

    Item 2(e).

    CUSIP No.:

    36870H103

     

    Item 3.

    Not Applicable.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of cover page.

     

      (b)

    Percent of class:

    See Row 11 of cover page.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See Row 5 of cover page for the Reporting Person.

     

      (ii)

    Shared power to vote or to direct the vote:

    See Row 6 of cover page for the Reporting Person. 

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for the Reporting Person.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for the Reporting Person.


    CUSIP No. 36870H103    SCHEDULE 13G    Page 4 of 5

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not Applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certifications.

    Not applicable.


    CUSIP No. 36870H103    SCHEDULE 13G    Page 5 of 5

     

    SIGNATURE

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 2, 2024      
         

    /s/ Aladar Szalay

          Aladar Szalay
    Get the next $GNLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNLX

    DatePrice TargetRatingAnalyst
    10/29/2024$8.00Buy
    Guggenheim
    8/28/2024$10.00Buy
    ROTH MKM
    11/27/2023$35.00Buy
    H.C. Wainwright
    9/12/2023$40.00Buy
    Maxim Group
    2/15/2023$10.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $GNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      6/7/24 9:45:20 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thomas John bought 2,500 shares, increasing direct ownership by 0.54% to 465,960 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      6/7/24 9:45:16 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smither John W bought 6,250 shares, increasing direct ownership by 90% to 13,170 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      6/7/24 9:45:18 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Genelux Corporation

      10-Q - GENELUX Corp (0001231457) (Filer)

      5/6/25 4:06:34 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Genelux Corporation

      10-K/A - GENELUX Corp (0001231457) (Filer)

      4/29/25 4:05:19 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Genelux Corporation

      S-8 - GENELUX Corp (0001231457) (Filer)

      3/28/25 4:29:17 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

      Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

      6/10/24 12:35:45 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Head of Regulatory Smalling Ralph was granted 4,172 shares, increasing direct ownership by 13% to 36,019 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:58:47 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Pharmaceutical Development Cappello Joseph was granted 13,350 shares, increasing direct ownership by 31% to 57,003 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:57:32 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Clinical Trial Operations Yu Yong was granted 13,350 shares, increasing direct ownership by 33% to 53,219 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:56:26 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

      WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.   "The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase 3 registrational trial in resistant/refractory ovarian cancer, promising early lung cancer clinical data from our ongoing Phase 1b/2 study, and increasing patient enrollment in our U.S. Ph

      5/6/25 4:10:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

      WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York. The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursday, May 8, 2025. A webcast link for the event will be available at https://wsw.com/webcast/jmp65/gnlx/1693890. An archived replay will be available for a

      5/1/25 4:05:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial results and business updates. "Our pr

      3/28/25 4:10:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Genelux Corporation Announces New Chief Financial Officer

      WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt's financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux," said Thomas Zindrick, President, CEO and Chairman of the Board. "His unique combination of financial expertise and scientific background will be valuable as the company continues building towards the potential launch of Olvi-Vec." Mr. Pulisic is an ac

      2/3/25 6:45:00 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Genelux Corporation

      SC 13G - GENELUX Corp (0001231457) (Subject)

      10/25/24 9:45:20 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Genelux Corporation

      SC 13G/A - GENELUX Corp (0001231457) (Subject)

      10/22/24 4:12:19 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genelux Corporation

      SC 13G - GENELUX Corp (0001231457) (Subject)

      2/2/24 4:06:25 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Genelux with a new price target

      Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

      10/29/24 6:26:41 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Genelux with a new price target

      ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

      8/28/24 7:46:18 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Genelux with a new price target

      H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00

      11/27/23 7:16:52 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care